Glycol-P (Propylene Glycol Oral Solution) 1.76 mg Solution is a Health Canada–registered veterinary drug (DIN 00560170) held by Vetoquinol N A Inc, containing Potassium Iodide. Health Canada lists its status as Cancelled Post Market (status date 24 Apr 2019). Nexara Health has matched 56 registrations of Potassium Iodide across 12 other regulated markets.

Health Canada registration

Potassium Iodide registered in other markets

56 registrations of the same molecule in 12 national registries outside Canada (first 39 shown, exact strength and form first). Each row is taken from the regulator's own published list; status is shown as the registry reports it.

See every manufacturer of Potassium Iodide worldwide →

Regulator price references for Potassium Iodide

Published list or reimbursement prices for Potassium Iodide presentations, in local currency, as at the date each registry last published. These are public reference prices, not Nexara Health quotes; strength and pack differ by row.

Sourcing through Nexara Health

Nexara Health is a Health Canada–licensed wholesaler (DEL #3-002896) in Winnipeg. This DIN is not currently marketed in Canada. The registrations above show which regulated markets hold an equivalent presentation that can be sourced for clinical comparator use or on a named-patient basis under Health Canada's Special Access Programme. Request a quote or read how named-patient and foreign-pack supply works in Canada.

Frequently asked questions

Is Glycol-P (Propylene Glycol Oral Solution) (DIN 00560170) marketed in Canada?

No. Health Canada lists DIN 00560170 as Cancelled Post Market as of 24 Apr 2019.

Who holds the Canadian licence for this product?

Vetoquinol N A Inc is the company of record in the Health Canada Drug Product Database.

Is Potassium Iodide registered outside Canada?

Yes — Nexara Health has matched 56 registrations in 12 other markets (see the table above).

Where does this data come from?

Health Canada Drug Product Database (DPD), DIN 00560170, status date 2019-04-24; national medicine registries: BDA, DH Drug Office, EDE, FDA NDC, HPRA, Lyfjastofnun lyfjaverdskra, Medicines Authority, NHS dm+d VMP, PBS, SFDA, SUKL DLP, TFDA; price sources: EDE, Lyfjastofnun lyfjaverdskra, SFDA. Nexara Health re-checks these sources weekly and shows the last verification date at the top of the page.

Source: Health Canada Drug Product Database (DPD), DIN 00560170, status date 2019-04-24; national medicine registries: BDA, DH Drug Office, EDE, FDA NDC, HPRA, Lyfjastofnun lyfjaverdskra, Medicines Authority, NHS dm+d VMP, PBS, SFDA, SUKL DLP, TFDA; price sources: EDE, Lyfjastofnun lyfjaverdskra, SFDA.

Health Canada Drug Product Database (DPD), DIN 00560170, status date 2019-04-24; national medicine registries: BDA, DH Drug Office, EDE, FDA NDC, HPRA, Lyfjastofnun lyfjaverdskra, Medicines Authority, NHS dm+d VMP, PBS, SFDA, SUKL DLP, TFDA; price sources: EDE, Lyfjastofnun lyfjaverdskra, SFDA. Last reviewed 2026-09-17. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.